ACORN CAPITAL ADVISORS, LLC
Filing Date
Global Rank
#2,957
/ 8,603
▼ 56
· as of Mar 2026
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+91.6%
Period ended 3 months ago
Filed May 15, 2026 · 55d
6 quarters · since Dec 2024
Clone Performance
Feb 2025–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+34.6%
SPY
+24.4%
Annualised alpha
+6.8%
Max drawdown
−47.3%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
21 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
23.4%
−8.6 pts
Top 5
68.3%
−5.4 pts
Top 10
88.2%
−2.8 pts
HHI
1,259
Diversified−340
Portfolio Trend
6 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $393,383,952 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
4 positions
Trimmed
Positions the filer reduced
5 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| JSPR | Jasper Therapeutics, Inc. | −375,000 | 1,411,492 | $1,236,466 | |
| CRDF | Cardiff Oncology, Inc. | −200,000 | 1,762,084 | $2,854,576 | |
| QTTB | Q32 Bio Inc. | −178,373 | 315,052 | $2,022,633 | |
| HELP | Cybin Inc. | −32,757 | 1,540,266 | $7,393,276 | |
| CGON | CG Oncology, Inc. | −1,000 | 1,130,501 | $76,512,307 | |
| No positions match the current search. | |||||
Sold Out
Positions the filer fully exited
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | 405,237 | $976,621 | |
| No positions match the current search. | ||||
21 positions ·
$393,383,952 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
Held | 1,746,264 | $92,063,038 | 23.40% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
Reduced | 1,130,501 | $76,512,307 | 19.45% | |
| BCAB |
BioAtla, Inc.
Healthcare
|
Added | 5,406,345 | $43,521,077 | 11.06% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
Added | 1,673,420 | $30,088,091 | 7.65% | |
| PBYI |
Puma Biotechnology, Inc.
Healthcare
|
Held | 4,131,299 | $26,399,000 | 6.71% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Held | 2,144,844 | $25,587,988 | 6.50% | |
| CADL |
Candel Therapeutics, Inc.
Healthcare
|
Added | 3,497,948 | $17,139,945 | 4.36% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
Held | 643,382 | $12,796,867 | 3.25% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Held | 2,839,674 | $11,756,250 | 2.99% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
NEW | 786,760 | $11,053,978 | 2.81% | |
| TARA |
Protara Therapeutics, Inc.
Healthcare
|
Held | 1,752,115 | $9,128,519 | 2.32% | |
| VSTM |
Verastem, Inc.
Healthcare
|
Held | 1,469,153 | $7,786,510 | 1.98% | |
| HELP |
Cybin Inc.
Healthcare
|
Reduced | 1,540,266 | $7,393,276 | 1.88% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Added | 634,539 | $6,523,060 | 1.66% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
Held | 595,744 | $3,985,527 | 1.01% | |
| WHWK |
Whitehawk Therapeutics, Inc.
Healthcare
|
Held | 1,139,363 | $3,930,802 | 1.00% | |
| CRDF |
Cardiff Oncology, Inc.
Healthcare
|
Reduced | 1,762,084 | $2,854,576 | 0.73% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
Reduced | 315,052 | $2,022,633 | 0.51% | |
| KPTI |
Karyopharm Therapeutics Inc.
Healthcare
|
NEW | 287,826 | $1,603,190 | 0.41% | |
| JSPR |
Jasper Therapeutics, Inc.
Healthcare
|
Reduced | 1,411,492 | $1,236,466 | 0.31% | |
| VYNE |
VYNE Therapeutics Inc.
Healthcare
|
Held | 1,425 | $852 | 0.00% |